Peter Wehrwein

As cell and gene therapies move beyond ultra-rare disease indications into broader patient populations, the commercialization infrastructure built around them is due for a fundamental redesign.

Medicare-eligible patients need to be enrolled in registry to get Medicare coverage for the anti-beta amyloid drug that is priced to cost $26,500 a year.